Document Detail

Are the cardiovascular effects and '5-HT syndrome' induced by MDL 73,975 and flesinoxan in the dog mediated by 5-HT1A receptors?
MedLine Citation:
PMID:  7813585     Owner:  NLM     Status:  MEDLINE    
The cardiovascular effects of the 5-HT1A receptor agonists MDL 73,975 (8-[2-(2,3-dihydro-8-methoxy-1,4-benzodoxin-2-yl)methylaminol++ +]-ethyl]-8- azaspiro[4,5]decane-7,9-dione hydrochloride) and flesinoxan (10-300 micrograms/kg subcutaneously, s.c.), the 5-HT1A receptor antagonist NAN 190 (2-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-1H-isoindole-1,3(2H)- dione,1,2-ethanedioate), and the alpha 1-adrenoceptor antagonist prazosin have been investigated in conscious normotensive and renal hypertensive dogs. In normotensive dogs the increases in heart rate and respiratory rate induced by both agonists were dose-related, as were the decreases in systolic and diastolic blood pressure induced by MDL 73,975. Both compounds caused a dose-related increase in the intensity of the '5-HT syndrome'. After pretreatment with NAN 190 (100 micrograms/kg s.c.) the increases in heart rate, respiratory rate and symptoms of the '5-HT syndrome' were significantly reduced but the decreases in systolic and diastolic pressure were additive. Pretreatment with prazosin (100 micrograms/kg s.c.) antagonized the '5-HT syndrome' and the increase in respiratory rate. Similar responses were evident in renal hypertensive dogs. Tolerance did not develop to the increases in heart rate, respiratory rate and manifestations of the '5-HT syndrome' in normotensive dogs during 5 days of treatment with MDL 73,975 or flesinoxan. In conclusion, MDL 73,975 and flesinoxan induced a 5-HT1A receptor-mediated fall in blood pressure but the changes in heart rate, respiratory rate and the '5-HT syndrome' are probably mediated by alpha 1-adrenoceptors.
G F Di Francesco
Related Documents :
3840055 - Analgesia and autonomic function following intrathecal administration of morphine and n...
7813585 - Are the cardiovascular effects and '5-ht syndrome' induced by mdl 73,975 and flesinoxan...
2826065 - Dissociation of norepinephrine turnover from alpha-2 responses after clorgiline.
6678385 - Comparison of intramuscularly and intravenously administered clonidine in the treatment...
25156645 - Impact on pulmonary arterial pressures after repeated endovascular thrombectomy of dial...
17890965 - Reactive rise in blood pressure upon cuff inflation: cuff inflation at the arm causes a...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  European journal of pharmacology     Volume:  262     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1995-02-08     Completed Date:  1995-02-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  205-15     Citation Subset:  IM    
Marion Merrell Dow, Strasbourg, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Antihypertensive Agents / administration & dosage,  pharmacology,  therapeutic use
Behavior, Animal / drug effects
Blood Pressure / drug effects
Disease Models, Animal
Dose-Response Relationship, Drug
Heart Rate / drug effects
Hypertension, Renal / drug therapy,  physiopathology
Injections, Subcutaneous
Piperazines / administration & dosage,  pharmacology*
Prazosin / administration & dosage,  pharmacology,  therapeutic use
Receptors, Serotonin / drug effects,  physiology*
Receptors, Serotonin, 5-HT1
Respiration / drug effects
Serotonin Agonists / administration & dosage,  pharmacology*,  therapeutic use
Serotonin Antagonists / administration & dosage,  pharmacology*,  therapeutic use
Spiro Compounds / administration & dosage,  pharmacology*
Reg. No./Substance:
0/Antihypertensive Agents; 0/MDL 73975; 0/Piperazines; 0/Receptors, Serotonin; 0/Receptors, Serotonin, 5-HT1; 0/Serotonin Agonists; 0/Serotonin Antagonists; 0/Spiro Compounds; 115338-32-4/1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine; 19216-56-9/Prazosin; 98206-10-1/flesinoxan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  BW1003C87 and NBQX but not CGS19755 reduce glutamate release and cerebral ischemic necrosis.
Next Document:  Effects of Trolox C and SIN-1 on arachidonic acid metabolism and on cyclic GMP formation in leukocyt...